Invivyd (IVVD) Research & Development (2021 - 2026)
Invivyd's (IVVD) quarterly Research & Development came in at $10.0 million in Q4 2025, down 43.9% YoY from $17.9 million in Q4 2024, and up 24.88% on a QoQ basis from $8.0 million in Q3 2025.
Invivyd (IVVD) Research & Development (2021 - 2026) Analysis & Trends
Invivyd (IVVD) has 5 years of Research & Development data on file, last reported at $10.0 million in Q4 2025.
- Quarterly Research & Development fell 43.9% year-over-year to $10.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $38.3 million (down 72.09% YoY) and the FY2025 annual result came in at $38.3 million, down 72.09% from the prior year.
- Research & Development rose to $10.0 million in Q4 2025, from $8.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $92.0 million in Q1 2022 to a low of $8.0 million in Q3 2025.
- A 5-year average of $34.8 million and a median of $30.7 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development surged 212.59% — and 2025, when it plunged 86.09%.
- Tracing IVVD's Research & Development over 5 years: stood at $68.4 million in 2021, then sank by 70.89% to $19.9 million in 2022, then surged by 212.59% to $62.3 million in 2023, then sank by 71.24% to $17.9 million in 2024, then slumped by 43.9% to $10.0 million in 2025.
- The last three Research & Development figures came in at $10.0 million (Q4 2025), $8.0 million (Q3 2025), and $9.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | 29.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.37 Mn |
| Dec 31, 2025 | 10.05 Mn |
| Sep 30, 2025 | 8.05 Mn |
| Jun 30, 2025 | 9.57 Mn |
| Mar 31, 2025 | 10.64 Mn |
| Dec 31, 2024 | 17.91 Mn |
| Sep 30, 2024 | 57.85 Mn |
| Jun 30, 2024 | 30.33 Mn |
| Mar 31, 2024 | 31.16 Mn |
| Dec 31, 2023 | 62.27 Mn |
| Sep 30, 2023 | 25.57 Mn |
| Jun 30, 2023 | 43.62 Mn |
| Mar 31, 2023 | 27.20 Mn |
| Dec 31, 2022 | 19.92 Mn |
| Sep 30, 2022 | 30.13 Mn |
| Jun 30, 2022 | 37.13 Mn |
| Mar 31, 2022 | 92.04 Mn |
| Dec 31, 2021 | 68.43 Mn |
| Sep 30, 2021 | 45.37 Mn |
| Jun 30, 2021 | 35.07 Mn |